{"product_id":"rapid-acting-antidepressants-hardback-9780128201893","title":"Rapid Acting Antidepressants (Hardback) 9780128201893","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eRapid Acting Antidepressants\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cp\u003eProvides the authority and expertise of leading contributors who discuss advances in pharmacology\u003c\/p\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eRonald S. Duman (Volume editor), John H. Krystal (Volume editor)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780128201893, Elsevier Science\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 26 June 2020\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e402 pages\u003cbr\u003e22.9 x 15.1 x 2.7 cm, 0.77 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eThe \u003ci\u003eAdvances in Pharmacology \u003c\/i\u003eseries presents a variety of chapters from the best authors in the field.\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cb\u003e \u003c\/b\u003e\u003cp\u003ePart I – Neurobiology of ketamine effects\u003c\/p\u003e \u003col\u003e \u003col\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eEffects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmission\u003c\/li\u003e \u003ci\u003e \u003c\/i\u003e\u003cp\u003eAllie J. Widman and Lori L. McMahon\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eAntidepressant mechanisms of ketamine: Focus on GABAergic inhibition\u003c\/li\u003e \u003ci\u003e \u003c\/i\u003e\u003cp\u003eBernhard Luscher, Mengyang Feng and Sarah J. Jefferson\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eThe role of eEF2 kinase in the rapid antidepressant actions of ketamine\u003c\/li\u003e \u003ci\u003e \u003c\/i\u003e\u003cp\u003eKanzo Suzuki and Lisa M. Monteggia\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003ePart II – The rapid therapeutic effects of ketamine\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eClinical overview of NMDA-R antagonists and clinical practice\u003c\/li\u003e \u003ci\u003e \u003c\/i\u003e\u003cp\u003ePasha A. Davoudian and Samuel T. Wilkinson\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eKetamine for depression clinical issues\u003c\/li\u003e \u003ci\u003e \u003c\/i\u003e\u003cp\u003eSyed Z. Iqbal and Sanjay J. Mathew\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eChronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence \u003c\/li\u003e \u003ci\u003e \u003c\/i\u003e\u003cp\u003eLynnette A. Averill, Samar Fouda, James W. Murrough and Chadi G. Abdallah\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eNeurobiological biomarkers of response to ketamine\u003c\/li\u003e \u003ci\u003e \u003c\/i\u003e\u003cp\u003eBashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter, Stephen Murata, Nimesha Gerlus and Carlos A. Zarate Jr\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eRelapse prevention in treatment resistant major depressive disorder with rapid-acting antidepressants\u003c\/li\u003e \u003ci\u003e \u003c\/i\u003e\u003cp\u003eJaskaran B. Singh, Maggie Fedgchin, Ella J. Daly and Wayne C. Drevets\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eThe emergence of ketamine as a novel treatment for posttraumatic stress disorder\u003c\/li\u003e \u003ci\u003e \u003c\/i\u003e\u003cp\u003eAdriana Feder, Sarah B. Rutter, Daniela Schille and Dennis S. Charney\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003ePart III – Novel rapid-acting antidepressant mechanisms related to ketamine\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\n\u003cli\u003emGlu2\/3 receptor as a novel target for rapid acting antidepressants\u003c\/li\u003e \u003ci\u003e \u003c\/i\u003e\u003cp\u003eShigeyuki Chaki\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eInvolvement of muscarinic receptor mechanisms in antidepressant drug action\u003c\/li\u003e \u003ci\u003e \u003c\/i\u003e\u003cp\u003eJeffrey M. Witkin, Jodi L. Smith, Lalit K. Golani, Emily A. Brooks and Anna E. Martin\u003c\/p\u003e\n\u003cb\u003e \u003c\/b\u003e\u003cp\u003e \u003c\/p\u003e\n\u003cli\u003eThe antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions\u003c\/li\u003e \u003c\/ol\u003e\n\u003c\/ol\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eWayne C. Drevets, Anindya Bhattacharya and Maura L. Furey\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Pharmacology [\u003ca title=\"See our other books on Pharmacology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Pharmacology%20%5BMMG%5D%22\"\u003eMMG\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Academic Press","offers":[{"title":"Default Title","offer_id":46650164707608,"sku":"9780128201893","price":148.78,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/products\/9780128201893.jpg?v=1694106135","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/rapid-acting-antidepressants-hardback-9780128201893","provider":"Freshly Printed Books","version":"1.0","type":"link"}